Last Updated : September 9, 2021
Details
FilesGeneric Name:
durvalumab
Project Status:
Complete
Therapeutic Area:
Extensive-stage small cell lung cancer
Manufacturer:
AstraZeneca Canada Inc.
Brand Name:
Imfinzi
Project Line:
Reimbursement Review
Project Number:
PC0234-000
Tumour Type:
Lung
NOC Status at Filing:
Post NOC
Performance Metric:
Achieved
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
As per Health Canada indication: in combination with etoposide and either carboplatin or cisplatin is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC).
Submission Type:
Initial
Fee Schedule:
Schedule A
Indications:
IMFINZI in combination with etoposide and either carboplatin or cisplatin is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC).
Recommendation Type:
Reimburse with clinical criteria and/or conditions
Final Recommendation:
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.
Key Milestones2 | |
---|---|
Call for patient/clinician input open | 03-Nov-20 |
Call for patient/clinician input closed | 24-Dec-20 |
Clarification: - Patient input submission received from Lung Cancer Canada and Lung Health Foundation | |
Submission received | 01-Dec-20 |
Submission accepted | 15-Dec-20 |
Review initiated | 16-Dec-20 |
Draft CADTH review report(s) provided to sponsor for comment | 22-Mar-21 |
Deadline for sponsors comments | 31-Mar-21 |
CADTH responses on draft review report(s) provided to sponsor | 03-May-21 |
Expert committee meeting (initial) | 14-May-21 |
Draft recommendation issued to sponsor | 31-May-21 |
Draft recommendation posted for stakeholder feedback | 10-Jun-21 |
End of feedback period | 24-Jun-21 |
Final recommendation issued to sponsor and drug plans | 09-Jul-21 |
Final recommendation posted | 27-Jul-21 |
Deadline for sponsor to submit redaction requests on draft CADTH review report(s) | 23-Jul-21 |
CADTH review report(s) posted | 09-Sep-21 |
Files
Last Updated : September 9, 2021